scholarly journals Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion

Oncogene ◽  
2012 ◽  
Vol 32 (9) ◽  
pp. 1110-1120 ◽  
Author(s):  
S Wei ◽  
X Chen ◽  
K McGraw ◽  
L Zhang ◽  
R Komrokji ◽  
...  
Keyword(s):  
Myelodysplastic Syndrome ◽  
Chromosome 5Q ◽  
5Q Deletion

A decade of progress in myelodysplastic syndrome with chromosome 5q deletion

Leukemia ◽  
2018 ◽  
Vol 32 (7) ◽  
pp. 1493-1499 ◽  
Author(s):  
Alan List ◽  
Benjamin L. Ebert ◽  
Pierre Fenaux
Keyword(s):  
Myelodysplastic Syndrome ◽  
Chromosome 5Q ◽  
5Q Deletion

scholarly journals Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion

Haematologica ◽  
2009 ◽  
Vol 95 (3) ◽  
pp. 406-414 ◽  
Author(s):  
M. Ximeri ◽  
A. Galanopoulos ◽  
M. Klaus ◽  
A. Parcharidou ◽  
K. Giannikou ◽  
...  
Keyword(s):  
Myelodysplastic Syndrome ◽  
Chromosome 5Q ◽  
5Q Deletion

scholarly journals Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Bagi Jana ◽  
Anas Khanfar ◽  
Mary Ninan
Keyword(s):  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Significant Risk ◽  
Cytogenetic Response ◽  
Antiangiogenic Activity ◽  
Meaningful Activity ◽  
Chromosome 5Q ◽  
Risk Of Progression ◽  
Bone Marrow Disorder ◽  
5Q Deletion

Myelodysplastic syndrome (MDS) is a clonal bone marrow disorder characterized by ineffective hematopoiesis. It is characterized by peripheral blood cytopenia and significant risk of progression to acute myeloid leukemia result. Deletion of the long arm of chromosome 20 (20q deletion) is present in 3–7% of patients with MDS. Lenalidomide is an immunomodulatory agent with antiangiogenic activity. It is FDA approved for the treatment of anemia in patients with low or int-1 risk MDS with chromosome 5q deletion with or without additional cytogenetic abnormalities. Study of lenalidomide in patients with MDS without 5q deletion but other karyotypic abnormalities demonstrated meaningful activity in transfusion dependent patients; however, response of patients with isolated 20q deletion to lenalidomide is not known. We are reporting a patient with 20q deletion MDS treated with lenalidomide after he failed to respond to azacytidine; to our knowledge this is the first report of a patient with isolated 20q deletion treated with lenalidomide.

Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion

2011 ◽  
Vol 91 (2) ◽  
pp. 309-310 ◽  
Author(s):  
Laura Cannella ◽  
Roberto Latagliata ◽  
Massimo Breccia ◽  
Ida Carmosino ◽  
Giuseppina Loglisci ◽  
...  
Keyword(s):  
Myelodysplastic Syndrome ◽  
Short Term ◽  
Chromosome 5Q ◽  
5Q Deletion

P095 Chromosome 5q deletion in myelodysplastic syndrome

2007 ◽  
Vol 31 ◽  
pp. S91
Author(s):  
J. Dwilewicz-Trojaczek ◽  
K. Madry ◽  
M. Paluszewska ◽  
E. Wiater ◽  
A. Szmigielska ◽  
...  
Keyword(s):  
Myelodysplastic Syndrome ◽  
Chromosome 5Q ◽  
5Q Deletion

Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion

2011 ◽  
Vol 35 (9) ◽  
pp. e175-e176
Author(s):  
Sondes Hadiji Mseddi ◽  
Faten Kallel ◽  
Olfa Kassar ◽  
Moez Elloumi ◽  
Ines Jedidi ◽  
...  
Keyword(s):  
Myelodysplastic Syndrome ◽  
Chromosome 5Q ◽  
5Q Deletion

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

2006 ◽  
Vol 355 (14) ◽  
pp. 1456-1465 ◽  
Author(s):  
Alan List ◽  
Gordon Dewald ◽  
John Bennett ◽  
Aristotle Giagounidis ◽  
Azra Raza ◽  
...  
Keyword(s):  
Myelodysplastic Syndrome ◽  
Chromosome 5Q ◽  
5Q Deletion
Sign in / Sign up

Export Citation Format

Share Document